Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
3
Neutral
6
Bullish
5
Bearish
7
Neutral
6
Bullish
33
Bearish
4
Neutral
0
Bullish
28
Discovery themes featuring this stock
Investor Presentation
Q4 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY23
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY22
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Wockhardt Limited is a global pharmaceutical and biotechnology company with a strong focus on research-driven pharmaceuticals, particularly in antibiotics and biotech drug development.
The company achieved a notable 67% growth in EBITDA in the past year, driven by operational excellence and significant debt reduction initiatives, improving its financial health markedly.
Wockhardt's rich pipeline includes multiple new chemical entities (NCEs), unique antibiotics that address superbug challenges, illustrating its leadership in novel antibiotic discovery, especially with successful Phase 3 trials for drugs like ZAYNICH.
Wockhardt plans to double its business in the next three years by expanding capacity and tapping into the growing demand for its diabetes and novel antibiotic portfolios, highlighting strategic growth plans.
It has garnered significant global recognition with Qualified Infectious Disease Programme status for five antibacterial drugs from the USFDA, underlining its global standing in addressing serious infectious diseases.
Pharmaceuticals & Biotechnology
Pharmaceuticals
29,782 Cr
Low Risk
139.8
33.9
1.2
6.0
2,420.00
1,086.80
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2265.50 | 37,413 Cr | 36.42 | 3.61 | 0.88 | 9.92 | 14.02 | 8.21 | ||
2171.00 | 36,834 Cr | 35.55 | 16.24 | 2.62 | 45.69 | 61.23 | 23.96 | ||
2200.10 | 35,382 Cr | 49.87 | 8.51 | 1.00 | 17.06 | 22.99 | 14.28 | ||
1729.90 | 32,809 Cr | 35.49 | 6.63 | 0.21 | 18.67 | 21.76 | 9.79 | ||
1832.85 | 29,782 Cr | 139.82 | 6.03 | 0.00 | 5.75 | 7.39 | 2.31 | ||
3215.40 | 26,325 Cr | 73.89 | 15.92 | 0.08 | 21.54 | 28.77 | 17.96 | ||
1181.90 | 25,217 Cr | 72.27 | 10.15 | 0.00 | 14.05 | 18.23 | 9.62 | ||
| Median: 7 Co. | — | 2171.00 | 32,809 Cr | 49.87 | 8.51 | 0.21 | 17.06 | 21.76 | 9.79 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Wockhardt Ltd (WOCKPHARMA) is currently trading at 1,927.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Wockhardt Limited is a global pharmaceutical and biotechnology company with a strong focus on research-driven pharmaceuticals, particularly in antibiotics and biotech drug development. The company achieved a notable 67% growth in EBITDA in the past year, driven by operational excellence and significant debt reduction initiatives, improving its financial health markedly. Wockhardt's rich pipeline includes multiple new chemical entities (NCEs), unique antibiotics that address superbug challenges, illustrating its leadership in novel antibiotic discovery, especially with successful Phase 3 trials for drugs like ZAYNICH. Wockhardt plans to double its business in the next three years by expanding capacity and tapping into the growing demand for its diabetes and novel antibiotic portfolios, highlighting strategic growth plans. It has garnered significant global recognition with Qualified Infectious Disease Programme status for five antibacterial drugs from the USFDA, underlining its global standing in addressing serious infectious diseases.
Over the past 52 weeks, Wockhardt Ltd has traded between a low of ₹1,086.80 and a high of ₹2,420.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Wockhardt Ltd has a market capitalization of approximately 29,782.38. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Wockhardt Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 139.82 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 29,782.38 Cr, Wockhardt Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Wockhardt Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Wockhardt Ltd is 139.82. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Zaynich is Wockhardt’s novel injectable antibiotic for severe drug-resistant infections, and it received US FDA approval on May 29.
Zaynich is a novel antibiotic developed in India by Wockhardt. The company said it achieved 96.8% efficacy in Phase 3 trials and has drawn US and European regulatory attention.
Wockhardt expects to launch Zaynich in the US within 6-8 months, with another stated target of end of calendar year 2026 or early 2027.
Wockhardt said CDSCO approved the import and marketing of Zaynich (Zidebactam/Cefepime) in India for adults with complicated urinary tract infections, including pyelonephritis, and cases with concurrent Gram-negative bacteremia.
